Brooks Laboratories Limited (BOM:533543)

Market Cap	1.72B -57.0%
Revenue (ttm)	888.46M +15.4%
Net Income	216.03M
EPS	7.40
Shares Out	n/a
PE Ratio	7.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,664
Average Volume	12,320
Open	61.16
Previous Close	61.16
Day's Range	57.84 - 61.16
52-Week Range	58.25 - 165.95
Beta	n/a
RSI	29.76
Earnings Date	May 18, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 323
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 533543

Financial Performance

In fiscal year 2025, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2024.